CSIMarket
 
Lixte Biotechnology Holdings Inc   (LIXT)
Other Ticker:  
 
 
Price: $2.3100 $0.04 1.762%
Day's High: $2.5699 Week Perf: -7.88 %
Day's Low: $ 2.30 30 Day Perf: -13.48 %
Volume (M): 3 52 Wk High: $ 9.50
Volume (M$): $ 8 52 Wk Avg: $2.46
Open: $2.33 52 Wk Low: $0.47



 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings Inc is a biopharmaceutical company based in East Setauket, New York. It focuses on developing novel drugs for the treatment of various cancers. The company's primary focus is on developing inhibitors of protein phosphatases, which are involved in regulating critical signaling pathways in cancer cells. Lixte Biotechnology aims to identify and develop targeted therapies that can potentially improve the outcomes of cancer patients. The company's research and development efforts primarily involve preclinical studies and early-stage clinical trials to evaluate the safety and efficacy of its drug candidates.


   Company Address: 680 East Colorado Boulevard Pasadena 91101 CA
   Company Phone Number: 830-7092   Stock Exchange / Ticker: NASDAQ LIXT
   LIXT is expected to report next financial results on March 28, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings Inc. Faces Setback with Operating Loss in Q3 2023



Pharmaceutical preparations sector advisors have started analyzing the financial performance of Lixte Biotechnology Holdings Inc for the third quarter of 2023. Despite the company not reporting any top-line figures yet, there are positive signs to signify progress. This article will outline the key facts and interpret the financial results, providing investors with a clearer understanding of Lixte Biotechnology's current standing.
Operating Loss:
Lixte Biotechnology Holdings Inc recorded an operating loss of $-1.024181 million in the third quarter of 2023. While the absence of top-line figures is noteworthy, the operating loss shows improvement compared to the same quarter in 2022, which reported a loss of $-1.478501 million. This reduction in operating loss signals positive growth and has given investors affirmation about Lixte Biotechnology's potential.

Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings Inc Reports Operating Loss of $-1.67 million in Financial Quarter Ending Jun 30, 2023



Lixte Biotechnology Holdings Inc, a major player in the pharmaceutical preparations sector, recently released its second-quarter financial numbers. As industry insiders analyze the figures, concerns arise surrounding the company's dismal performance. The absence of a specified top-line for the April to June 2023 quarter is a glaring issue, giving rise to speculation about the company's financial struggles. This article aims to delve into the financial woes faced by Lixte Biotechnology Holdings Inc, highlighting their growing operating loss and a concerning shortfall compared to the previous year.
Operating Loss Amplifies:
Lixte Biotechnology Holdings Inc's second-quarter analysis reveals a distressing operating loss of $-1.669998 million. Yet, the company fails to provide any information regarding its top-line during this period. This omission raises concerns about the company's ability to generate revenue and meet financial obligations. It is surprising that a rising player in the industry, with apparent growth potential, has not been forthcoming with its financial performance.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com